- Home
- ATXS vs IGR Comparison
ATXS vs IGR Comparison
Compare ATXS & IGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- IGR
- Stock Information
- Founded
- ATXS 2008
- IGR 2004
- Country
- ATXS United States
- IGR United States
- Employees
- ATXS N/A
- IGR N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- IGR Finance Companies
- Sector
- ATXS Health Care
- IGR Finance
- Exchange
- ATXS Nasdaq
- IGR Nasdaq
- Market Cap
- ATXS 676.1M
- IGR 776.6M
- IPO Year
- ATXS 2015
- IGR N/A
- Fundamental
- Price
- ATXS $12.46
- IGR $5.01
- Analyst Decision
- ATXS Buy
- IGR
- Analyst Count
- ATXS 7
- IGR 0
- Target Price
- ATXS $30.00
- IGR N/A
- AVG Volume (30 Days)
- ATXS 4.1M
- IGR 747.7K
- Earning Date
- ATXS 11-12-2025
- IGR 01-01-0001
- Dividend Yield
- ATXS N/A
- IGR 13.93%
- EPS Growth
- ATXS N/A
- IGR N/A
- EPS
- ATXS N/A
- IGR N/A
- Revenue
- ATXS N/A
- IGR N/A
- Revenue This Year
- ATXS N/A
- IGR N/A
- Revenue Next Year
- ATXS N/A
- IGR N/A
- P/E Ratio
- ATXS N/A
- IGR N/A
- Revenue Growth
- ATXS N/A
- IGR N/A
- 52 Week Low
- ATXS $3.56
- IGR $3.88
- 52 Week High
- ATXS $12.55
- IGR $5.70
- Technical
- Relative Strength Index (RSI)
- ATXS 84.72
- IGR 46.82
- Support Level
- ATXS $11.83
- IGR $4.92
- Resistance Level
- ATXS $12.16
- IGR $5.20
- Average True Range (ATR)
- ATXS 0.36
- IGR 0.08
- MACD
- ATXS 0.26
- IGR -0.01
- Stochastic Oscillator
- ATXS 97.97
- IGR 36.54
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About IGR CBRE Global Real Estate Income Fund of Beneficial Interest
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.